Category: Intellectual property
-
Patent Awarded for Nasal Delivered Cancer Immunotherapy
A technology for cancer therapies that harnesses the immune system with nanoscale droplets suspended in an emulsion and delivered through the nose received a U.S. patent.
-
Univ. Licenses Barrett’s Esophagus Detection Device
A medical device company is licensing a minimally-invasive technology developed in university labs for detection of Barrett’s esophagus, a condition that often leads to esophageal cancer.
-
Genetic Repair Company Starts-Up, Gains $87 Million
A company is getting underway to develop therapies that extend genome editing to repair genetic disruptions, not just remove them from DNA.
-
Genentech Gains Microbe Drug Discovery Tech in $1B Deal
Biotechnology company Genentech is licensing a process from a start-up enterprise that discovers small molecule drugs from naturally occurring microbes found in soil.
-
Lilly, Cell Implants Start-Up Partner on Diabetes
Eli Lilly and Company is licensing a technology for implanting pancreatic beta cells in people with type 1 diabetes, from Sigilon Therapeutics Inc., an enterprise making implants of live cells to treat chronic diseases.
-
New Company Acquires Off-the-Shelf T-Cell Cancer Therapies
A new enterprise is formed to develop treatments for cancer using donated T-cells from the immune system, rather than the patient’s own T-cells, engineered to attack cancer cells.
-
Cough Suppressant Produced from Engineered Yeast Cells
A bioengineering group created a process for producing a cough suppressant in the lab, usually derived from opium poppies, but instead from genetically modified brewer’s yeast.
-
Antibodies Licensed for Multi-Target Immunotherapies
MedImmune, the biologics subsidiary of drug maker AstraZeneca, is licensing antibodies from a biotechnology company for treatments that simultaneously address two or more cancer targets.
-
Patent Awarded for Nanoparticle Drug, Cannabis Delivery
A delivery technology for therapeutic compounds in nanoscale natural oil particles received a U.S. patent, which the company owning the technology says can be applied to drugs, nutritional supplements, and cannabis-based treatments.
-
Novartis Licenses Biomaterial for Cancer Immunotherapy
Drug maker Novartis is licensing from a lab at Harvard University a biocompatible material designed to provide delivery of treatments that invoke the immune system to fight cancer.